Subretinal fluid morphology in chronic central serous chorioretinopathy and its relationship to treatment: a retrospective analysis on PLACE trial data.

"Funding: This research was supported by the Stichting Blindenhulp, Mathilde Grant, Stichting Leids Oogheelkundig Ondersteuningsfonds, Rotterdamse Stichting Blindenbelangen, Stichting Ooglijders, Stichting tot Verbetering van het Lot der Blinden, and the Netherlands Organisation for Scientific Research (NWO). The funding organizations Macula Fonds, Retina Nederland Onderzoek Fonds, Landelijke Stichting voor Blinden en Slechtzienden, Algemene Nederlandse Vereniging ter Voorkoming van Blindheid, and Stichting Blinden‐Penning contributed through UitZicht. The aforementioned founding funding sources provided unrestricted grants and had no role in the design or conduct of this research."

"This was a retrospective clinical study based on the data that were collected prospectively in the PLACE trial (ClinicalTrials.gov: NCT01797861, EudraCT: 2012‐004555‐36). The PLACE trial was an investigator‐initiated, open‐label, multicentre, randomized controlled trial, which compared half‐dose PDT to HSML treatment (Breukink et al. ; van Dijk et al. ). Informed consent was obtained from all participants. Institutional review board approval was obtained from all participating centres and all aspects of this study adhered to the tenets of the Declaration of Helsinki. Details of the study design are available in the previously published protocol (Breukink et al. ). For the current study, we obtained data from one study centre (Leiden University Medical Center, Leiden, the Netherlands). We only included data from eyes of which the available OCT scans contained the entire area of SRF accumulation. This was to allow accurate estimates of SRF morphology, especially in terms of SRF width and SRF volume which otherwise would be impossible if only a part of the SRF was visible on the available OCT scan. No meaningful a priori power calculation was possible for this exploratory imaging study."